Liver cancer drugs under Real-World watch in korea

NCT ID NCT06544629

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study monitors the safety and effectiveness of two drugs, Imjudo and Imfinzi, for people with liver cancer (hepatocellular carcinoma) in Korea. About 246 patients who are already eligible for these drugs under Korean guidelines will be observed in real-world settings. The goal is to track side effects and how well the drugs control the cancer, but this is not a cure study.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    RECRUITING

    Busan, South Korea

  • Research Site

    RECRUITING

    Goyang, South Korea

  • Research Site

    RECRUITING

    Seongnam, South Korea

  • Research Site

    RECRUITING

    Seoul, South Korea

  • Research Site

    NOT_YET_RECRUITING

    Seoul, South Korea

  • Research Site

    RECRUITING

    Suwon, South Korea